Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer

被引：0
|
作者：
Eun Kyoung Jeon
Hye-Sung Won
Yoon-Ho Ko
In Seok Lee
Tae Ho Hong
Young Kyoung You
Myung Ah Lee
机构：
[1] Seoul St. Mary’s Hospital,Division of Oncology, Department of Internal Medicine
[2] Catholic University,Division of Oncology, Department of Internal Medicine
[3] Uijeongbu St. Mary’s Hospital,Division of Gastroenterology, Department of Internal Medicine
[4] Catholic University,Department of Surgery
[5] Seoul St. Mary’s Hospital,undefined
[6] Catholic University,undefined
[7] Seoul St. Mary’s Hospital,undefined
[8] Catholic University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2012年 / 138卷
关键词：
Pancreatic cancer; Gemcitabine; Erlotinib; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1625 / 1630
页数：5
相关论文
共 50 条
  • [41] Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.
    Cho, Jangho
    Lim, Jae Yun
    Cho, Jae Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells
    Torres, Carolina
    Linares, Ana
    Jose Alejandre, Maria
    Jesus Palomino-Morales, Rogelio
    Ramon Delgado, Juan
    Perales, Sonia
    PANCREAS, 2016, 45 (02) : 269 - 280
  • [43] Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer
    Heinemann, V.
    Hoehler, T.
    Seipelt, G.
    Wein, A.
    Golf, A.
    Mahlberg, R.
    Schmid, B.
    Boeck, S.
    Neugebauer, S.
    Hochhaus, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 209 - 209
  • [44] Efficacy of gemcitabine in advanced unresectable biliary tract cancer
    Mehrotra, B
    Ahmed, S
    Bhargava, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 377S - 377S
  • [45] Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
    Kobayashi, Satoshi
    Suzuki, Motoko
    Ueno, Makoto
    Maruki, Yuta
    Okano, Naohiro
    Todaka, Akiko
    Ozaka, Masato
    Tsuji, Kunihiro
    Shioji, Kazuhiko
    Doi, Keitaro
    Kojima, Yasushi
    Tsumura, Hidetaka
    Tanaka, Kazunari
    Higuchi, Hajime
    Kawabe, Ken
    Imaoka, Hiroshi
    Yamashita, Tatsuya
    Miwa, Haruo
    Nagano, Hiroaki
    Arima, Shiho
    Hayashi, Hideyuki
    Naganuma, Atsushi
    Yamaguchi, Hironori
    Hisano, Terumasa
    Umemoto, Kumiko
    Ishii, Shuji
    Nakashima, Koji
    Suzuki, Rei
    Kitano, Yohei
    Misumi, Toshihiro
    Furuse, Junji
    Ishii, Hiroshi
    ONCOLOGIST, 2022, 27 (10): : E774 - E782
  • [46] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 25 - 25
  • [47] Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
    Heinemann, Volker
    Vehling-Kaiser, Ursula
    Waldschmidt, Dirk
    Kettner, Erika
    Maerten, Angela
    Winkelmann, Cornelia
    Klein, Stefan
    Kojouharoff, Georgi
    Gauler, Thomas C.
    von Weikersthal, Ludwig Fischer
    Clemens, Michael R.
    Geissler, Michael
    Greten, Tim F.
    Hegewisch-Becker, Susanna
    Rubanov, Oleg
    Baake, Gerold
    Hoehler, Thomas
    Ko, Yon D.
    Jung, Andreas
    Neugebauer, Sascha
    Boeck, Stefan
    GUT, 2013, 62 (05) : 751 - 759
  • [48] Gemcitabine plus capecitabine in elderly patients with advanced pancreatic cancer
    Vasiliki, Michalaki
    Andreas, Poydorou
    Antonios, Vezakis
    Georgios, Frangulidis
    Theodosios, Theodosopoulos
    Christos, Papadimitriou
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Induction Gemcitabine Plus Concurrent Gemcitabine and Radiotherapy for Locally Advanced Unresectable or Resected Pancreatic Cancer
    Youl, M.
    Hashem, S.
    Brade, A.
    Cummings, B.
    Dawson, L. A.
    Gallinger, S.
    Hedley, D.
    Jiang, H.
    Kim, J.
    Krzyzanowska, M. K.
    Ringash, J.
    Wong, R.
    Brierley, J.
    CLINICAL ONCOLOGY, 2014, 26 (04) : 203 - 209
  • [50] Biweekly treatment with Docetaxel-Gemcitabine and Erlotinib in patients with metastatic and/or unresectable pancreatic cancer offers a survival benefit
    Samelis, G.
    Tsiakou, A.
    Karamanides, M.
    Pelechrini, M.
    Zaganides, A.
    Ekmektzoglou, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
12345